Details

Autor(en) / Beteiligte

• Qu, Wei-Feng
• Zhou, Pei-Yun
• Liu, Wei-Ren
• Tian, Meng-Xin
• Jin, Lei
• Jiang, Xi-Fei
• Wang, Han
• Tao, Chen-Yang
• Fang, Yuan
• Zhou, Yu-Fu
• Song, Shu-Shu
• Ding, Zhen-Bin
• Peng, Yuan-Fei
• Dai, Zhi
• Qiu, Shuang-Jian
• Zhou, Jian
• Fan, Jia
• Tang, Zheng
• Shi, Ying-Hong

Titel

Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection

Ist Teil von

• Annals of translational medicine, 2020-04, Vol.8 (7), p.487-487

Ort / Verlag

China: AME Publishing Company

Erscheinungsjahr

2020

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Comorbidity among cancer patients is prevalent and influential to prognosis after operation. Limited data are available on comorbidity evaluations in patients with intrahepatic cholangiocarcinoma (ICC). This study aimed to assess the comorbidity distribution in ICC patients and to adapt the Charlson Comorbidity Index (CCI) or the age-adjusted CCI (ACCI) for survival prediction. The study cohort included 268 ICC patients treated with curative surgery from January 2000 to December 2007 at the Department of Liver Surgery, Zhongshan Hospital. The association between the comorbidity index and overall survival (OS) or disease-free survival (DFS). was analyzed by the Kaplan-Meier method. Multivariable analysis was established to select the determinant parameters. Major comorbid conditions of ICC patients included liver disease, hypertension, diabetes and ulcer. The median follow-up time was 25.5 months in the whole data set. Among the entire cohort, the 1-, 3- and 5-year OS rates were 55.3%, 26.0% and 15.6%, respectively. In multivariate analysis, the ACCI correlated with OS, and higher scores were associated with poorer prognosis (hazard ratio =1.134, 95% confidence interval: 1.015-1.267 and P value =0.026). CCI was not an independent predictive factor for OS or DFS. In contrast to CCI, ACCI was a more promising model to accurately predict OS in ICC patients who underwent liver resection. Further research should be focused on the impact of comorbidity therapies.